Nature Communications (Jan 2021)
A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy
- Laetitia Douguet,
- Serena Janho dit Hreich,
- Jonathan Benzaquen,
- Laetitia Seguin,
- Thierry Juhel,
- Xavier Dezitter,
- Christophe Duranton,
- Bernhard Ryffel,
- Jean Kanellopoulos,
- Cecile Delarasse,
- Nicolas Renault,
- Christophe Furman,
- Germain Homerin,
- Chloé Féral,
- Julien Cherfils-Vicini,
- Régis Millet,
- Sahil Adriouch,
- Alina Ghinet,
- Paul Hofman,
- Valérie Vouret-Craviari
Affiliations
- Laetitia Douguet
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Serena Janho dit Hreich
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Jonathan Benzaquen
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Laetitia Seguin
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Thierry Juhel
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Xavier Dezitter
- Inserm, CHU Lille, U1286—Infinite—Institute for Translational Research in Inflammation, University of Lille
- Christophe Duranton
- Université Côte d’Azur, CNRS, INSERM, LP2M
- Bernhard Ryffel
- INEM—UMR7355, Institute of Molecular Immunology and Neurogenetic, University and CNRS
- Jean Kanellopoulos
- Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Université Paris-Saclay
- Cecile Delarasse
- INSERM, CNRS, Institut de la Vision, Sorbonne Université
- Nicolas Renault
- Inserm, CHU Lille, U1286—Infinite—Institute for Translational Research in Inflammation, University of Lille
- Christophe Furman
- Inserm, CHU Lille, U1286—Infinite—Institute for Translational Research in Inflammation, University of Lille
- Germain Homerin
- Inserm, CHU Lille, U1286—Infinite—Institute for Translational Research in Inflammation, University of Lille
- Chloé Féral
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Julien Cherfils-Vicini
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Régis Millet
- Inserm, CHU Lille, U1286—Infinite—Institute for Translational Research in Inflammation, University of Lille
- Sahil Adriouch
- Institute for Research and Innovation in Biomedicine, Normandie University
- Alina Ghinet
- Inserm, CHU Lille, U1286—Infinite—Institute for Translational Research in Inflammation, University of Lille
- Paul Hofman
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- Valérie Vouret-Craviari
- Université Côte d’Azur, CNRS, INSERM, IRCAN
- DOI
- https://doi.org/10.1038/s41467-021-20912-2
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 17
Abstract
A limited percentage of patients with non-small cell lung cancer respond to immunotherapy. Here the authors show that HEI3090, a chemical positive modulator of the purinergic P2RX7 receptor, promotes IL-18 mediated anti-tumor immune responses and sensitizes lung cancer to anti-PD-1 therapy in preclinical models.
